• Lilly’s DTC Obesity Push, Layoffs, and an Eye on Ocular Diseases

  • Sep 4 2024
  • Duración: 13 m
  • Podcast

Lilly’s DTC Obesity Push, Layoffs, and an Eye on Ocular Diseases

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Eli Lilly shook up the weight loss market again last week, announcing plans to sell single-dose vials of its blockbuster GLP-1 drug Zepbound directly to consumers. Meanwhile, Novo Nordisk said Monday that it expects the shortage for the lower doses of its own GLP-1 therapy Ozempic to persist into the fourth quarter of 2024.

    This week, we take a closer look at eyes, where gene therapy is breaking through against wet AMD, a common cause of blindness—potentially significantly minimizing the number of treatments required by patients—and cell therapy is making strides against another common foe: dry eye disease.

    Lastly, an unfortunate trend—layoffs—continues to play out, with BioMarin, Genentech and Astellas Gene Therapies all parting with staff members.

    Más Menos
activate_WEBCRO358_DT_T2
Ciencias Biológicas
Más Menos

Lo que los oyentes dicen sobre Lilly’s DTC Obesity Push, Layoffs, and an Eye on Ocular Diseases

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles